Data From Biogen Idec, Inc. (Massachusetts) (BIIB)’s Portfolio Of Multiple Sclerosis Therapies And Pipeline Featured At Medical Congresses
5/30/2014 7:26:39 AM
Biogen Idec (NASDAQ: BIIB) today announced that more than 60 company-sponsored presentations highlighting key data from its industry-leading portfolio of marketed and investigational multiple sclerosis (MS) therapies are being featured during two neurology conferences, further demonstrating its commitment to meeting the individual needs of MS patients and improving outcomes with research that addresses important efficacy and safety questions.
Help employers find you! Check out all the jobs and post your resume.
comments powered by